Literature DB >> 21733820

The BATTLE to personalize lung cancer prevention through reverse migration.

Kathryn A Gold1, Edward S Kim, J Jack Lee, Ignacio I Wistuba, Carol J Farhangfar, Waun Ki Hong.   

Abstract

Agents can enter clinical development for cancer prevention either initially or after previous development for a different indication, such as arthritis, with both approaches consuming many years of development before an agent is fully evaluated for cancer prevention. We propose the following, third approach: reverse migration, that is, importing agents, targets, and study designs to personalize interventions and concepts developed in advanced cancer to the setting of cancer prevention. Importing these "ready-made" features from therapy will allow reverse migration to streamline preventive agent development. We recently reported the Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial of personalized lung cancer therapy and now propose the reverse migration development of personalized lung cancer prevention based on the BATTLE model.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21733820      PMCID： PMC3171137          DOI： 10.1158/1940-6207.CAPR-11-0232

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN： 1940-6215


  108 in total

1.  Cotargeting cyclin D1 starts a new chapter in lung cancer prevention and therapy.

Authors:  Edward S Kim; J Jack Lee; Ignacio I Wistuba
Journal:  Cancer Prev Res (Phila)       Date:  2011-06

Review 2.  Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward.

Authors:  Gary J Kelloff; Scott M Lippman; Andrew J Dannenberg; Caroline C Sigman; Homer L Pearce; Brian J Reid; Eva Szabo; V Craig Jordan; Margaret R Spitz; Gordon B Mills; Vali A Papadimitrakopoulou; Reuben Lotan; Bharat B Aggarwal; Robert S Bresalier; Jeri Kim; Banu Arun; Karen H Lu; Melanie E Thomas; Helen E Rhodes; Molly A Brewer; Michele Follen; Dong M Shin; Howard L Parnes; Jill M Siegfried; Alison A Evans; William J Blot; Wong-Ho Chow; Patricia L Blount; Carlo C Maley; Kenneth K Wang; Stephen Lam; J Jack Lee; Steven M Dubinett; Paul F Engstrom; Frank L Meyskens; Joyce O'Shaughnessy; Ernest T Hawk; Bernard Levin; William G Nelson; Waun Ki Hong
Journal:  Clin Cancer Res       Date:  2006-06-15       Impact factor: 12.531

3.  Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations.

Authors:  Yelena Y Janjigian; Bernard J Park; Maureen F Zakowski; Marc Ladanyi; William Pao; Sandra P D'Angelo; Mark G Kris; Ronglai Shen; Junting Zheng; Christopher G Azzoli
Journal:  J Thorac Oncol       Date:  2011-03       Impact factor: 15.609

4.  Genetic variation in 3-hydroxy-3-methylglutaryl CoA reductase modifies the chemopreventive activity of statins for colorectal cancer.

Authors:  Steven M Lipkin; Elizabeth C Chao; Victor Moreno; Laura S Rozek; Hedy Rennert; Mila Pinchev; Diana Dizon; Gad Rennert; Levy Kopelovich; Stephen B Gruber
Journal:  Cancer Prev Res (Phila)       Date:  2010-04-19

5.  EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the EUropean Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups.

Authors:  N van Zandwijk; O Dalesio; U Pastorino; N de Vries; H van Tinteren
Journal:  J Natl Cancer Inst       Date:  2000-06-21       Impact factor: 13.506

6.  Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.

Authors:  Peter S Hammerman; Martin L Sos; Alex H Ramos; Chunxiao Xu; Amit Dutt; Wenjun Zhou; Lear E Brace; Brittany A Woods; Wenchu Lin; Jianming Zhang; Xianming Deng; Sang Min Lim; Stefanie Heynck; Martin Peifer; Jeffrey R Simard; Michael S Lawrence; Robert C Onofrio; Helga B Salvesen; Danila Seidel; Thomas Zander; Johannes M Heuckmann; Alex Soltermann; Holger Moch; Mirjam Koker; Frauke Leenders; Franziska Gabler; Silvia Querings; Sascha Ansén; Elisabeth Brambilla; Christian Brambilla; Philippe Lorimier; Odd Terje Brustugun; Aslaug Helland; Iver Petersen; Joachim H Clement; Harry Groen; Wim Timens; Hannie Sietsma; Erich Stoelben; Jürgen Wolf; David G Beer; Ming Sound Tsao; Megan Hanna; Charles Hatton; Michael J Eck; Pasi A Janne; Bruce E Johnson; Wendy Winckler; Heidi Greulich; Adam J Bass; Jeonghee Cho; Daniel Rauh; Nathanael S Gray; Kwok-Kin Wong; Eric B Haura; Roman K Thomas; Matthew Meyerson
Journal:  Cancer Discov       Date:  2011-06       Impact factor: 39.397

7.  Allergic inflammation does not impact chemical-induced carcinogenesis in the lungs of mice.

Authors:  Konstantinos Doris; Sophia P Karabela; Chrysoula A Kairi; Davina Cm Simoes; Charis Roussos; Spyros G Zakynthinos; Ioannis Kalomenidis; Timothy S Blackwell; Georgios T Stathopoulos
Journal:  Respir Res       Date:  2010-08-26

8.  Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.

Authors:  Sao Jiralerspong; Shana L Palla; Sharon H Giordano; Funda Meric-Bernstam; Cornelia Liedtke; Chad M Barnett; Limin Hsu; Mien-Chie Hung; Gabriel N Hortobagyi; Ana M Gonzalez-Angulo
Journal:  J Clin Oncol       Date:  2009-06-01       Impact factor: 44.544

9.  PIK3CA mutations and copy number gains in human lung cancers.

Authors:  Hiromasa Yamamoto; Hisayuki Shigematsu; Masaharu Nomura; William W Lockwood; Mitsuo Sato; Naoki Okumura; Junichi Soh; Makoto Suzuki; Ignacio I Wistuba; Kwun M Fong; Huei Lee; Shinichi Toyooka; Hiroshi Date; Wan L Lam; John D Minna; Adi F Gazdar
Journal:  Cancer Res       Date:  2008-09-01       Impact factor: 12.701

10.  The chemopreventive agent myoinositol inhibits Akt and extracellular signal-regulated kinase in bronchial lesions from heavy smokers.

Authors:  Wei Han; Joell J Gills; Regan M Memmott; Stephen Lam; Phillip A Dennis
Journal:  Cancer Prev Res (Phila)       Date:  2009-03-31
View more
  26 in total

Review 1.  Acquisition and processing of endobronchial ultrasound-guided transbronchial needle aspiration specimens in the era of targeted lung cancer chemotherapy.

Authors:  William Bulman; Anjali Saqi; Charles A Powell
Journal:  Am J Respir Crit Care Med       Date:  2011-10-27       Impact factor: 21.405

2.  The cytochrome P450 enzyme CYP24A1 increases proliferation of mutant KRAS-dependent lung adenocarcinoma independent of its catalytic activity.

Authors:  Wei Huang; Paramita Ray; Wenbin Ji; Zhuwen Wang; Derek Nancarrow; Guoan Chen; Stefanie Galbán; Theodore S Lawrence; David G Beer; Alnawaz Rehemtulla; Nithya Ramnath; Dipankar Ray
Journal:  J Biol Chem       Date:  2020-03-12       Impact factor: 5.157

3.  Transcriptomic architecture of the adjacent airway field cancerization in non-small cell lung cancer.

Authors:  Humam Kadara; Junya Fujimoto; Suk-Young Yoo; Yuho Maki; Adam C Gower; Mohamed Kabbout; Melinda M Garcia; Chi-Wan Chow; Zuoming Chu; Gabriella Mendoza; Li Shen; Neda Kalhor; Waun Ki Hong; Cesar Moran; Jing Wang; Avrum Spira; Kevin R Coombes; Ignacio I Wistuba
Journal:  J Natl Cancer Inst       Date:  2014-02-22       Impact factor: 13.506

Review 4.  Biomarkers and sustainable innovation in cardiovascular drug development: lessons from near and far afield.

Authors:  Russell M Medford; T Forcht Dagi; Robert S Rosenson; Margaret K Offermann
Journal:  Curr Atheroscler Rep       Date:  2013-05       Impact factor: 5.113

Review 5.  Pulmonary adenocarcinoma: a renewed entity in 2011.

Authors:  Humam Kadara; Mohamed Kabbout; Ignacio I Wistuba
Journal:  Respirology       Date:  2012-01       Impact factor: 6.424

Review 6.  Precision medicine clinical trials: defining new treatment strategies.

Authors:  Brandy M Heckman-Stoddard; Judith J Smith
Journal:  Semin Oncol Nurs       Date:  2014-05       Impact factor: 2.315

7.  Into the eye of the storm: breast cancer's somatic mutation landscape points to DNA damage and repair.

Authors:  Joanne Ngeow; Emily Nizialek; Charis Eng
Journal:  Transl Cancer Res       Date:  2013-04       Impact factor: 1.241

8.  G-protein coupled receptor family C, group 5, member A (GPRC5A) expression is decreased in the adjacent field and normal bronchial epithelia of patients with chronic obstructive pulmonary disease and non-small-cell lung cancer.

Authors:  Junya Fujimoto; Humam Kadara; Melinda M Garcia; Mohamed Kabbout; Carmen Behrens; Diane D Liu; J Jack Lee; Luisa M Solis; Edward S Kim; Neda Kalhor; Cesar Moran; Amir Sharafkhaneh; Reuben Lotan; Ignacio I Wistuba
Journal:  J Thorac Oncol       Date:  2012-12       Impact factor: 15.609

9.  Ewing's sarcoma: overcoming the therapeutic plateau.

Authors:  Vivek Subbiah; Razelle Kurzrock
Journal:  Discov Med       Date:  2012-06       Impact factor: 2.970

10.  Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib.

Authors:  Mizuki Nishino; Suzanne E Dahlberg; Linnea E Fulton; Subba R Digumarthy; Hiroto Hatabu; Bruce E Johnson; Lecia V Sequist
Journal:  Acad Radiol       Date:  2016-01-08       Impact factor: 3.173
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.